Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Study of Omalizumab in Chronic Spontaneous Urticaria Refractory to H1 Antihistamines
jRCT2080222712Phase 3
- Sponsor
- Novartis
- Start
- Jan 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of omalizumab in chronic idiopathic urticaria (CIU) (3 arms), sponsored by Novartis.
02
Drugs
omalizumab
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on jRCT2080222712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222712.